Status:

RECRUITING

Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment

Lead Sponsor:

Peking University People's Hospital

Conditions:

Endometrium Cancer

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

In this study, overweight and obese patients with endometrial cancer treated with fertility- sparing therapy were randomly divided into two groups. The test group was given weight management, while th...

Detailed Description

Obesity is recognized as a major risk factor for the development of endometrial cancer. Notably, several retrospective studies have shown that obesity reduces complete remission and pregnancy rates an...

Eligibility Criteria

Inclusion

  • age ≥18 years old
  • diagnosed as endometrial cancer or atypical hyperplasia
  • immunohistochemical staining and sequencing of pathological tissue
  • fertility-preserving therapy
  • BMI≥25 kg/m2
  • informed consent.

Exclusion

  • those with communication barriers
  • pregnant women
  • medical and surgical serious complications: urinary calculi, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes mellitus, active gallbladder disease, fat dyspepsia, severe cardiovascular and cerebrovascular diseases.

Key Trial Info

Start Date :

April 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2026

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT06169449

Start Date

April 1 2022

End Date

December 31 2026

Last Update

September 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking University People's Hospital

Beijing, China, China, 100044